biostudies-literatureBakai TAAssociation Nationale de la Recherche et de la TechnologieRégion Auvergne-Rhône-AlpesAssociation Nationale de la Recherche et de la Technologie (ANRT)EPIMOD400https://www.ebi.ac.uk/biostudies/studies/S-EPMC9804945biostudies-literatureUnknown21(1)<h4>Background</h4>In 2012, the World Health Organization (WHO) recommended seasonal malaria chemoprevention (SMC) in areas of high seasonal transmission. Though implemented since 2013, the effectiveness of SMC in Togo was never evaluated.<h4>Methods</h4>This study concerned routine data from 2013 to 2020 mass SMC campaigns for children under five in all health facilities of three Regions of Togo. Treatment coverage, reasons for non-treatment, and SMC-attributable adverse reactions were analysed per year and treatment round. Random effect logistic models estimated SMC effectiveness per health district, year, and treatment round.<h4>Results</h4>The overall coverage was 98% (7,971,877 doses for 8,129,668 children). Contraindication was the main reason for non-administration. Over the study pMalaria journalEffectiveness of seasonal malaria chemoprevention in three regions of Togo: a population-based longitudinal study from 2013 to 2020.PMC9804945Grant 19 003 721 01CIFRE 2017/1805Thomas ARabilloud MAtcha-Oubou TVoirin NTchadjobo TKhanafer NIwaz JBakai TAfalseEffectiveness of seasonal malaria chemoprevention in three regions of Togo: a population-based longitudinal study from 2013 to 2020.<h4>Background</h4>In 2012, the World Health Organization (WHO) recommended seasonal malaria chemoprevention (SMC) in areas of high seasonal transmission. Though implemented since 2013, the effectiveness of SMC in Togo was never evaluated.<h4>Methods</h4>This study concerned routine data from 2013 to 2020 mass SMC campaigns for children under five in all health facilities of three Regions of Togo. Treatment coverage, reasons for non-treatment, and SMC-attributable adverse reactions were analysed per year and treatment round. Random effect logistic models estimated SMC effectiveness per health district, year, and treatment round.<h4>Results</h4>The overall coverage was 98% (7,971,877 doses for 8,129,668 children). Contraindication was the main reason for non-administration. Over the study p2022-01-01T00:00:00Z2022 Dec2025-05-29T16:22:40.83Z2025-05-29T16:22:40.83ZS-EPMC98049453658719110.1186/s12936-022-04434-w